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Abstract
Background: Preoperative permanent atrial fibrillation (AF) is associated with
impaired outcome after surgical aortic valve replacement (SAVR). The impact of pre-
operative paroxysmal AF, however, has remained elusive.
Purpose: We assessed the impact of preoperative paroxysmal AF on outcome in
patients undergoing SAVR with bioprosthesis.
Methods: A total of 666 patients undergoing isolated AVR with a bioprosthesis were
included. Survival data was obtained from the national registry Statistics Finland.
Patients were divided into three groups according to the preoperative rhythm: sinus
rhythm (n = 502), paroxysmal AF (n = 90), and permanent AF (n = 74).
Results: Patients in the sinus rhythm and paroxysmal AF groups did not differ with
respect to age (P = .484), gender (P = .402) or CHA2DS2-VASc score (P = .333). At
12-month follow-up, AF was present in 6.2% of sinus rhythm patients and in 42.4%
of paroxysmal AF patients (P < .001). During follow-up, incidence of fatal strokes in
the paroxysmal AF group was higher compared to sinus rhythm group (1.9 vs 0.4 per
100 patient-years, HR 4.4 95% Cl 1.8-11.0, P = .001). Cardiovascular mortality was
higher in the paroxysmal AF group than in the sinus rhythm group (5.0 vs 3.0 per
100 patient-years, HR 1.70 95% CI 1.05-2.76, P = .03) and equal to patients in the
permanent AF (5.0 per 100 patient-years).
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Conclusion: Patients undergoing SAVR with bioprosthesis and history of paroxysmal
AF had higher risk of developing permanent AF, cardiovascular mortality and inci-
dence of fatal strokes compared to patients with preoperative sinus rhythm. Life-long
anticoagulation should be considered in patients with a history of preoperative
paroxysmal AF.
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac tachyarrhythmia.
The prevalence of AF is 0.5% to 1% in general population, but
increases with aging and about 10% of octogenarians have AF.1-4 Per-
manent AF is associated with increased mortality and risk of thrombo-
embolic complications.5 In particular, the risk is increased in AF
patients with comorbidities such as hypertension, heart failure, coro-
nary artery disease, and valvular heart diseases.4,6-9 Thus, there is still
some debate whether AF is an independent predictor of adverse prog-
nosis or whether the worse prognosis among AF patients rather
reflects increased age and associated comorbidities. In addition, it is
controversial whether the risk related to AF is equal in patients with
paroxysmal and permanent AF. In recent guidelines the indications for
permanent oral anticoagulation are the same in different types of AF.10
Several studies have demonstrated that preoperative permanent
AF is a predictor of impaired outcome after adult cardiac surgery and
transcatheter aortic valve implantation (TAVI).7,8,10-15 However, the
impact of preoperative paroxysmal AF in these patients is less well
known. Namely, earlier studies included only patients with permanent
AF2,13,16 or patients with paroxysmal and permanent AF, were
pooled.4,14,17 Thus, the prognostic significance of paroxysmal AF has
remained elusive.
The aim of this multicenter study was to evaluate the impact of
preoperative paroxysmal and permanent AF on mortality and morbid-
ity after isolated bioprosthetic SAVR in comparison to patients in
sinus rhythm.
2 | METHODS
The CAREAVR is a Finnish multicenter, retrospective registry
(ClinicalTrials.gov Identifier: NCT02626871) evaluating the incidence
of AF, thromboembolic complications and bleeding events in patients
undergoing isolated SAVR with bioprosthesis.
2.1 | Patients and anticoagulation practice
Patient data were retrospectively reviewed from four Finnish univer-
sity hospitals (Helsinki, Kuopio, Oulu, and Turku) over the period
2003 to 2014 (in Helsinki 2006-2014). Hospital records were
reviewed for 721 patients who underwent SAVR with a biological
prosthesis. Patients with a history of cardiac surgery, permanent pace-
maker as well as those undergoing any other concomitant major car-
diac surgery procedure were excluded. In order to obtain complete
data on cardiovascular events, only patients from the hospitals' catch-
ment area were included in this registry.
The routine postoperative anticoagulation practice was oral war-
farin and subcutaneous enoxaparin started in the evening of the day
of surgery. Enoxaparin was continued until therapeutic INR > 2.0 was
reached. Warfarin was continued for 3 months unless there was an
indication for permanent anticoagulation. Antiplatelet agents were
not used routinely postoperatively. Medication was at the treating
physician's discretion.
2.2 | Data collection
Patient records were individually reviewed with a standardized struc-
tured data collection protocol for preoperative, perioperative, and dis-
charge data as well as for long-term follow-up events, such as AF,
mortality, and causes of death.
Preoperative history of AF was reviewed from the patient records
and based on 12-lead ECG, Holter-recording or telemonitoring. In
addition, the preoperative rhythm was confirmed from a 12-lead ECG
recorded during admission. Based on this information, the patients
were divided into three groups: (a) sinus rhythm group had no preop-
erative history of atrial fibrillation; (b) paroxysmal atrial fibrillation
group had preoperatively at least one documented episode of atrial
fibrillation cardioverted or with spontaneous recovery of sinus rhythm
within 7 days and (c) permanent atrial fibrillation group had continu-
ous atrial fibrillation prior to surgery. The presence of AF during
follow-up was assessed from 12-lead ECG recorded at 3 and
12 months postoperative visits and whenever patients was admitted
to hospital due to suspicion of symptomatic AF.
The risk of thromboembolic complications was assessed with
the CHA2DS2-VASc score
18,19 and the BARC classification (Bleeding
Academic Research Consortium) was used to classify the bleeding
outcomes.20
The study endpoints were death from any cause, cardiovascular
death (cardiac death, death caused by stroke, and death due to
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TABLE 1 Preoperative clinical characteristics
Sinus rhythm Paroxysmal
P
Permanent
P(n = 502) AF (n = 90) AF (n = 74)
Age 74.8 ± 6.4 75.3 ± 6.8 .484 77.6 ± 5.1 <.001*
Male 194 (38.6) 39 (43.3%) .402 45 (60.8%) <.001*
BMI (kg/m2) 27.6 ± 4.8 26.0 ± 3.9 .060 28.9 ± 5.2 .204
CHA2DS2-VASc score 3.9 ± 1.5 4.1 ± 1.6 .333 4.6 ± 1.53 <.001*
CHADS2 score 2.1 ± 1.3 2.3 ± 1.2 .345 3.0 ± 1.2 <.001*
NYHA class .918 .755
1 70 (13.9%) 11 (12.2%) 10 (13.5%)
2 183 (36.5%) 32 (35.6%) 25 (33.8%)
3 218 (43.4%) 40 (44.4%) 32 (43.2%)
4 31 (6.2%) 7 (7.8%) 7 (9.5%)
Preoperative laboratory values
eGFR (mL/min) 75.8 ± 20.8 69.9 ± 22.2 .014* 69.8 ± 22.4 .023*
INR 1.1 ± 0.2 1.4 ± 0.7 <.001* 1.9 ± 0.5 <.001*
Medication
Beta Blockers 277 (55.2%) 73 (81.1%) <.001* 64 (86.5%) <.001*
ACEI/ARB 250 (49.8%) 38 (42.2%) .174 43 (58.1%) .193
Digoxin 6 (1.2%) 11 (12.2%) <.001* 29 (39.2%) <.001*
Warfarin 15 (3.0%) 37 (41.1%) <.001* 68 (91.9%) <.001*
Acetylsalicylic acid 287 (57.2%) 45 (50.0%) .223 7 (9.5%) <.001*
ADP inhibitor 7 (1.4%) 2 (2.2%) .631 1 (1.4%) 1.000
NSAID 13 (2.6%) 3 (3.3%) .722 0 (0.0%) .390
Comorbidities
COPD 89 (17.7%) 16 (17.8%) .996 15 (20.3%) .569
CAD 111 (22.1%) 24 (26.7%) .343 24 (32.4%) .050
Diabetes 90 (17.9%) 15 (16.7%) .767 21 (28.4%) .034*
Dyslipidemia 277 (55.2%) 57 (63.3%) .162 36 (48.6%) .276
Heart failure 210 (41.8%) 37 (41.1%) .970 45 (60.8%) .002
Hypertension 255 (50.8%) 71 (78.9%) .079 65 (87.8%) .002*
PAH 108 (21.5%) 28 (31.1%) .104 41 (55.4%) <.001*
PAD 25 (5.0%) 4 (4.4%) .816 6 (10.8%) .271
Stroke or TIA 70 (13.9%) 12 (13.3%) .918 12 (16.2%) .508
MI 25 (5.0%) 8 (8.9%) .137 6 (8.11%) .264
DVT 11 (2.2%) 4 (4.4%) .210 0 (0.0%) .082
AE 3 (0.6%) 0 (0.0%) 1.00 0 (0.0%) 1.00
PE 7 (1.4%) 1 (1.1%) .839 2 (2.7%) .325
Echocardiogram
LVEF (%) 60.6 ± 11.5 59.4 ± 14.1 .476 55.2 ± 14.1 .003*
LA (mm) 41.5 ± 6.5 44.8 ± 7.9 <.001* 50.5 ± 8.6 <.001*
AV gradient (mmHg) 81.8 ± 22.7 80.1 ± 19.3 .516 81.0 ± 24.4 .800
AR 263 (52.4%) 56 (62.2%) .124 40 (54.1%) 1.00
MR 262 (52.2%) 54 (60.0%) .196 52 (70.3%) .005*
Note: Values are mean + SD or n (%).
Abbreviations: ACEI, angiotensin-converting-enzyme inhibitor; ADP, inhibitor adenosine inhibitor; AE, arterial embolism; AR, aortic valve regurgitation;
ARB, angiotensin II receptor blocker; AV, aortic valve; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease;
DVT, deep venous thromboembolism; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; LA, left atrium; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; MR, mitral valve regurgitation; NSAID, non-steroidal anti-inflammatory drug; NYHA, New York Heart
Association Functional Classification; PAD, peripheral arterial disease; PAH, pulmonary artery hypertension; PE, pulmonary embolism.
*P < .05.
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bleeding), and other deaths. In Finland, data on deceased patients
including the causes of death are prospectively collected into a
national registry, Statistics Finland. This national registry was interro-
gated to retrieve the survival status and the eventual causes of death
which were classified according to the World Health Organization
ICD-10 classification.
The study protocol was approved by the Ethics Committee of the
Hospital District of Southwest Finland and of the National Institute for
Health and Welfare. Informed consent was not required because of
the retrospective, registry-based nature of the study. The study con-
forms to the Declaration of Helsinki. An independent, certified third-
party data monitor checked the integrity of the data of each study site.
2.3 | Statistical analysis
Continuous variables were reported as mean ± SD if normally distrib-
uted, and as median (inter-quartile range) if they were skewed. Con-
tinuous variables were compared with one-way ANOVA using LSD
post hoc test and categorical variables were compared using Chi-
Square test or Fisher's test. Survival time analysis was performed the
Cox proportional hazard model and expressed as incidence of events
per 100 patient-years. In addition, multivariate logistic regression
analysis was performed to adjust for the differences in preoperative
clinical characteristics between the sinus rhythm and paroxysmal AF
groups. A P-value of <.05 was considered statistically significant. Sta-
tistical analyses were conducted with SPSS software (version 22.0,
SPSS, IBM SPSS Inc.).
3 | RESULTS
A total of 666 patients undergoing isolated SAVR with a bioprosthesis
were included in the final analysis. Patients were divided into three
groups according to the history of preoperative rhythm: sinus rhythm
(n = 502), paroxysmal AF (n = 90), and permanent AF (n = 74). The
mean follow-up time was 4.9 ± 2.7 years.
In the baseline clinical characteristics the paroxysmal AF group
had larger left atrium diameter (P < .001), lower estimated glomerular
filtration rate (eGFR) (P = .014), higher INR (P < .001), and they were
more often on warfarin therapy (P < .001) compared to the sinus
rhythm group (Table 1). With respect to other baseline characteristics,
TABLE 2 Long-term follow-up data
Mortality
Sinus rhythm Paroxysmal AF Permanent AF
n = 502 n = 90 P-value (HR, 95% CI) n = 74 P-value (HR, 95% CI)
All cause 125 (24.9) [4.9] 30 (33.3) [7.2] .057 (HR 1.5, 95% Cl 1.0-2.2) 23 (31.1) [7.1] .055 (HR 1.6, 95% Cl 1.0-2.4)
1 year* 95.0% 87.8% 91.9%
3 year* 89.8% 82.2% 81.1%
5 year* 84.3% 75.6% 81.1%
Cardiovascular 75 (14.9) [3.0] 21 (23.3) [5.0] .032 (HR 1.7, 95% Cl 1.1–2.8) 16 (21.6) [5.0] .039 (HR 1.8, 95% Cl 1.0-3.1)
1 year* 96.0% 90% 94.6%
3 year* 93.2% 86.7% 85.1%
5 year* 90.6% 82.2% 85.1%
Cardiac 53 (10.6) [2.1] 11 (12.2) [2.6] .506 (HR 1.3, 95% Cl 0.7-2.4) 9 (12.2) [2.8] .355 (HR 1.4, 95% Cl 0.7-2.8)
Stroke 11 (2.2) [0.4] 8 (8.9) [1.9] .001 (HR 4.4, 95% Cl 1.8–11.0)* 4 (5.4) [1.2] .076 (HR 2.8, 95% Cl 0.9-8.9)
1 year* 99.2% 98.9% 98.6%
3 year* 98.8% 97.8% 97.3%
5 year* 98.4% 93.3% 97.3%
Bleeding 9 (1.8) [0.4] 3(3.3) [0.7] .234 (HR 2.2, 95% Cl 0.6-8.5) 5 (6.8) [1.6] .005 (HR 5.2 95% Cl 1.6–16.2)
1 year* 99.2% 97.8% 97.3%
3 year* 99.0% 97.8% 94.6%
5 year* 98.4% 97.8% 94.6%
Other vascular 6 (1.2) [0.2] 1 (1.1) [0.2] .919 (HR 1.1, 95% Cl 0.1-9.3) 1 (1.4) [0.3] .662 (HR 1.6, 95% Cl 0.2-13.5)
Non-cardiovascular 50 (10.0] [2.0] 9 (10.0) [2.2] .752 (HR 1.1, 95% Cl 0.6-2.3) 7 (9.5) [2.2] .649 (HR 1.2, 95% Cl 0.5-2.7)
Cancer 28 (5.6) [1.1] 4 (4.4) [1.0] .802 (HR 0.9, 95% Cl 0.3-2.5) 3 (4.1) [0.9] .905 (HR 0.9, 95% Cl 0.3-3.1)
Other 3 (0.6) [0.1] 0 (0.0) [0.0] .658 (HR 0.8, 95% Cl 0.04-15.4) 1 (1.4) [0.3] .403 (HR 2.6, 95% Cl 0.3-25.3)
Note: Values are n (%) and [incidence per 100 patient-years].
Abbreviations: AF, atrial fibrillation; HR, hazard ratio.
*Denotes survival.
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including age, sex, and CHA2DS2-VASc score, patients in the paroxys-
mal AF group and sinus rhythm group did not differ.
Patients with permanent AF were older (P < .001), had a higher
prevalence of male gender (P < .001), diabetes (P = .034), hyperten-
sion (P = .002), pulmonary hypertension (P < .001), heart failure
(P = .002), mitral valve regurgitation (P = .005), lower left ventricular
ejection fraction (P = .003), larger left atrium diameter (P < .001),
lower eGFR (P = .023), higher INR (P < .001), and higher CHA2DS2-
VASc score (P < .001) than the sinus rhythm patients (Table 1). In
addition, the permanent AF patients were more often on warfarin
(P < .001), beta blocker (P < .001), and digoxin (P < .001) medication
as well as used aspirin less frequently than the sinus rhythm patients
(Table 1).
3.1 | Late outcome
All-cause mortality in the paroxysmal AF group (7.2 per 100 patient-
years at risk) tended to be higher compared to the sinus rhythm
group (4.9 per 100 patient-years) (HR 1.5, 95% CI 1.0-2.2, P = .057)
(Table 2; Figures 1A and 2). The Kaplan-Meier estimates of survival
in the paroxysmal AF and sinus rhythm groups at 1, 3, and 5 years
were 87.8%, 82.2%, 75.6% and 95.0%, 89.8%, 84.3%, respectively
(Figure 1A). All-cause mortality in the permanent AF group (7.1 per
100 patient-years) also tended to be higher than in the sinus rhythm
group (HR 1.6, 95% CI 1.0-2.4, P = .055) with Kaplan Meier esti-
mates of survival at 1, 3, and 5 years of 91.9%, 81.1%, 81.1%,
respectively.
F IGURE 1 Kaplan-Meier curves for survival from: A, all-cause mortality; B, cardiovascular mortality; C, fatal stroke; and D, fatal bleeding in
patients undergoing isolated bioprosthetic surgical aortic valve replacement. AF, atrial fibrillation
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Cardiovascular mortality in the paroxysmal group (5.0 per
100 patient-years) was significantly higher compared to the sinus
rhythm group (3.0 per 100 patient-years) (HR 1.7 95% Cl 1.1-2.8,
P = .032) (Table 2; Figures 1B and 2). In particular, mortality from fatal
stroke was 1.9 per 100 patient-years in the paroxysmal AF patients as
compared to 0.4 per 100 patient-years in the sinus rhythm patients
(HR 4.4 95% Cl 1.8-11.0, P = .001) (Figures 1C and 2). Cardiovascular
mortality was also higher in the permanent AF group (5.0 per
100 patient-years) than in the sinus rhythm group (HR 1.8 95% Cl
1.0-3.1, P = .039). This was mainly due to high rate of fatal bleeds 1.6
per 100 patient-years compared to 0.3 per 100 patient-years in the
sinus rhythm patients (HR 5.2 95% Cl 1.6-16.2, P = .005 (Figure 1D).
Logistic regression analysis was also performed to adjust for the
differences in preoperative clinical characteristics (eGFR and left atrium
size) between the sinus rhythm and paroxysmal AF groups. After adjust-
ment of these, paroxysmal AF remained as an independent predictor of
fatal stoke (HR 3.4, 95% CI 1.2-9.8, P = .025). However, paroxysmal AF
lost its significance as predictor of cardiovascular mortality (HR 1.7,
95% CI 0.9-3.1, P = .126).
The majority of fatal strokes were of ischemic origin (81.8% in the
sinus rhythm group, and 75.0% in the paroxysmal and permanent AF
groups). The incidence of fatal ischemic strokes in the paroxysmal AF
group was higher compared to the sinus rhythm group (1.4 vs 0.4 per
100 patient years, HR 4.1, 95% CI 1.4-11.4, P = .008). There was also
a trend (albeit non-significant) of higher incidence of fatal hemorrhagic
strokes in the paroxysmal AF group (0.5 vs 0.1 per 100 patient years,
HR 6.0, 95% CI 0.8-42.7, P = .07).
The time to first stroke/TIA were 4.4 + 2.8 years for the sinus
rhythm group, 4.1 + 3.0 years for the paroxysmal AF group (P = .402
vs sinus rhythm group), and 3.5 + 2.7 years for the permanent AF
group (P = .017 vs sinus rhythm group). The time to the first major
bleed were 4.9 + 2.8 years in the sinus rhythm group, 4.2 + 3.0 years
for the paroxysmal AF group (P = .073 vs sinus rhythm group), and
3.7 + 2.7 years for the permanent AF group (P = .004 vs sinus rhythm
group).
At discharge, 3- and 12-months after surgery, AF was present in
38.9%, 36.6%, and 42.4% of patients in the paroxysmal AF group and
in 17.3%, 10.8%, and 6.2% of patients in the sinus rhythm group,
respectively (P < .001 for all) (Table 3). In the permanent AF group, AF
was detected in 90.5%, 85.2%, and 88.9% (P < .001 for all vs sinus
rhythm). Furthermore, AF (paroxysmal or permanent) was docu-
mented in 64% of the paroxysmal AF group patients during the
12-month follow-up after the discharge.
All patients were on warfarin therapy at 3-month follow-up visit.
Thereafter warfarin was continued in 59.2% of the paroxysmal AF
patients and in 31.9% of the sinus rhythm patients (P < .001)
(Table 3). At 12-month follow-up, 50% patients in the paroxysmal AF
patients and 35.9% in the sinus rhythm patients were on warfarin
F IGURE 2 Outcomes in patients with preoperative paroxysmal
atrial fibrillation vs preoperative sinus rhythm (hazard ratios and 95%
confidence intervals)
TABLE 3 Rhythm status, warfarin, and aspirin medication during follow-up
Sinus rhythm Paroxysmal AF Permanent AF
n = 502 n = 90 P-value n = 74 P-value
Rhythm = AF
At discharge 87 (17.3) 35 (38.9) <.001 67 (90.5) <.001
At 3 months 54 (10.8) 26 (36.6) <.001 52 (85.2) <.001
At 12 months 31 (6.2) 14 (42.4) <.001 40 (88.9) <.001
Medication
Warfarin after 3 months 87 (31.9) 42 (59.2) <.001 59 (98.3) <.001
Warfarin after 12 months 65 (35.9) 22 (50.0) .085 45 (97.8) <.001
2003-8/2006 13 (37.1) 2 (40.0) 1 (100.0)
9/2006-5/2010 27 (35.5) 14 (53.8) 19 (100.0)
6/2010-2014 25 (35.7) 6 (46.2) 25 (96.2)
ASA after 3 months 141 (51.8) 18 (25.4) <.001 4 (6.6) <.001
ASA after 12 months 94 (52.5) 16 (36.4) .055 3 (6.7) <.001
Note: Values are n (%).
Abbreviations: AF: Atrial fibrillation; ASA: aspirin.
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therapy with borderline difference between the groups (P = .085). In
the permanent AF group 98.3% and 97.8% of patients were on warfa-
rin at 3 and 12 months follow-up. There was no significant change in
the use of oral anticoagulation during the study period in the paroxys-
mal AF patients.
Of the patients suffering from fatal stroke, 87.5% in the paroxys-
mal AF, 14.2% in the sinus rhythm, and 75% in the permanent AF
group were on OAC at the time of event. However, only 14.2% of the
deceased patients in the paroxysmal AF group had INR within the tar-
get range (2.0-3.0). In the sinus rhythm and permanent AF groups
none of the patients had INR within the therapeutic range. In sinus
rhythm and permanent AF groups there were one patient in both
groups without INR value taken within 1 month preceding the event.
At 3-month follow-up visit, permanent aspirin treatment was pre-
scribed in 25.4% of the paroxysmal AF patients and 51.8% of the
sinus rhythm patients (P < .001). At 12-month follow-up aspirin was
used in 36.4% patients in the paroxysmal AF group and 52.5% in the
sinus rhythm group (P = .055). In the permanent AF group aspirin was
prescribed in 6.6% and 6.7% of patients at 3- and 12-month follow-
up, respectively (P < .001 for both vs sinus rhythm group) (Table 3).
4 | DISCUSSION
The main findings of the study were that patients with preoperative par-
oxysmal AF undergoing SAVR had high risk of developing permanent AF
during follow-up. In addition, they were at higher risk of cardiovascular
death than patients with sinus rhythm, the risk being similar to patients
with permanent AF. The increased mortality in paroxysmal AF patients
was mainly driven by fatal strokes. At the time of fatal stroke, INR was
not within the therapeutic range in a great majority of patients.
The finding of high risk of permanent AF and fatal strokes during
follow-up in patients with preoperative paroxysmal AF has pivotal
clinical implications in patient care. The data suggest that patients
with preoperative paroxysmal AF need to be considered as candidates
for life-long oral anticoagulation after bioprosthetic SAVR
irrespectively of their postoperative rhythm. Given the well-defined
therapeutic efficacy of oral anticoagulation therapy in permanent and
paroxysmal AF,21,22 the current guidelines recommend anti-
coagulation in patients with permanent and paroxysmal AF and risk
factors for stroke.10 In our study only a half of the patients with pre-
operative paroxysmal AF were on oral anticoagulation therapy
12 months postoperatively. Considering that 42% of patients with
preoperative paroxysmal AF were in AF at 12-month follow-up, it
seems that anticoagulation was prescribed only in paroxysmal AF
patients developing permanent AF during follow-up. Thus, the treat-
ment of paroxysmal AF patients, particularly those with a high risk of
developing permanent AF, seems to be far from optimal. In line with
the present findings, recently Mogensen et al reported that 53% of
their heart failure patients with paroxysmal AF were on anti-
coagulation.12 Palomäki et al evaluated patients with acute stroke or
transient ischemic attack and a history of AF.23 Of those that were
anticoagulation naive at time of the event, 50% had a history of
paroxysmal AF. The high incidence of permanent AF and the high risk
of fatal stroke in patients with a history of preoperative paroxysmal
AF undergoing bioprosthetic SAVR highlights the importance of life-
long anticoagulation in these patients.
Importantly, cardiovascular mortality in the paroxysmal AF patients
was significantly higher compared to those in sinus rhythm and of same
magnitude as in patients with permanent AF. This was somewhat sur-
prising since as comes to the preoperative clinical characteristics patients
with paroxysmal AF were well matched with their counterparts in sinus
rhythm. These two groups did not differ with respect cardiovascular risk
factors such as cardiac function, CHA2DS2-VASc score or other com-
orbidities, which are significant predictors of mortality and morbidity in
cardiac patients and patients with AF as well as also patient with bio-
prosthesis.24 Paroxysmal AF group had lower eGFR and larger left atrium
diameter. However, after adjustment of these, paroxysmal AF remained
as an independent predictor of fatal strokes.
In the present study fatal strokes were primarily responsible for
the high cardiovascular mortality in the paroxysmal AF patients with
4-fold risk compared to the sinus rhythm patients and 1.5-fold com-
pared to permanent AF patients. On the other hand, there was no sig-
nificant difference between patients with paroxysmal AF and sinus
rhythm with respect to cardiac deaths or non-cardiac deaths. Stroke
and other thromboembolic complications in AF patients are often of
embolic origin.25 Correspondingly, our results suggest that AF
resulting in cardio-embolism rather than heart failure or sudden death
were responsible for the increased mortality among patients with par-
oxysmal AF. Our results are also in line with a Danish study including
15 000 AF patients with heart failure.12 They reported that patients
with paroxysmal AF had higher risk of stroke than patients with sinus
rhythm or persistent or permanent AF. These findings suggest that in
spite of an increased risk of thromboembolism, anticoagulation ther-
apy has not been adopted properly in patients with paroxysmal AF
undergoing SAVR with a bioprosthesis.
What merits to be addressed is that only 14% of the paroxysmal
AF group patients suffering from fatal stroke and prescribed OAC had
INR preceding the event within the target range. Further, in the per-
manent AF group none had INR within the therapeutic range at the
time of bleeding event. These suggest that in most cases the events,
whether stroke or bleeding were related to poor anticoagulation con-
trol. This is in accordance with a previous report in patients with non-
valvular AF. In AF patients on OAC and suffering from stroke, INR at
the time of event was outside the therapeutic target in more than
50% of patients.23
Permanent AF is a well-known predictor of adverse outcomes in
patients scheduled for SAVR (14). However, to our best knowledge
there are no earlier studies addressing the question of paroxysmal AF
in patients undergoing SAVR with a bioprosthesis. A closest counter-
part to our study is a recent paper by Shaul et al.8 They evaluated the
differential impact of paroxysmal and permanent AF) on the outcome
after TAVI. In contrast to our findings, they reported that the risk of
death or stroke at 2 years was similar in patients with sinus rhythm
(16%) and paroxysmal AF (15%), whereas it was significantly higher
among patients with permanent AF (38%). Such differences might be
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explained by a different risk profile in TAVI patients compared to
patients undergoing SAVR with a bioprosthesis as well as by the fact
that temporary anticoagulation is not used after TAVI.26
Ngaage et al11 evaluated 252 patients with preoperative sinus
rhythm, 89 patients with intermittent (paroxysmal) AF and 34 with con-
tinuous (permanent) AF. Preoperative AF (including patients with parox-
ysmal and permanent AF) was associated with 50% increase in late all-
cause mortality but not with cardiac death. In our study all-cause mortal-
ity in patients with paroxysmal and permanent AF was also 50% higher
compared to patients in sinus rhythm. However, in contrast to us,
Ngaage et al11 reported a 9-fold incidence of cardiac death in patients
with permanent AF when compared to patients with paroxysmal AF
whereas in our study cardiac mortality in patients with paroxysmal and
permanent AF was of same magnitude. Whether the finding by Ngaage
was due to differences in comorbidities between the groups cannot be
addressed because the clinical characteristics of patients in the paroxys-
mal and permanent AF groups were not presented separately.
It is also of interest that in our study the incidence of permanent
AF during postoperative follow-up was very high among the patients
with preoperative paroxysmal AF. All patients with preoperative par-
oxysmal AF were in sinus rhythm at the time of surgery. However, a
substantial proportion (39%) was discharged in AF and at 3- and
12-month follow-up visits permanent AF was present in 37% and
42%, respectively. In addition, almost 2/3 of patients in the paroxys-
mal AF group had documented AF (paroxysmal of persistent) during
the first 12 months after the discharge. Most probably, the incidence
of AF would be even higher if an ambulatory ECG recording had been
applied. The high incidence of AF is in line with Ngaage et al who
reported that 50% of patients with preoperative paroxysmal AF
undergoing SAVR were in permanent AF during follow-up.11 In addi-
tion, we observed that in the paroxysmal AF patients, the incidence of
permanent AF increased by time whereas it decreased in the patients
with preoperative sinus rhythm during the follow-up. This suggests
that preoperative paroxysmal AF, even in the absence of other com-
orbidities, identifies a group of patients who are prone to develop per-
manent AF postoperatively. In addition, it seems that cardiac surgery
speeds up the progression from paroxysmal to permanent
AF. Mogensen et al12 reported that the risk of death and thromboem-
bolic complications was highest among patients with new onset
AF. The reason for this remains unclear, but a possible explanation is
that patients with new onset AF received less aggressive treatment to
control AF heart rate and are less often prescribed anticoagulation.
4.1 | Strengths and limitations
This study has several methodological strengths. The data were col-
lected from electronic patient records and hospital database in which
the data are stored prospectively in predefined form. A validated,
structured case report form was used. A quality control monitoring of
the data was performed by a clinical research organization. The
patient population comes from the hospital regional catchment area
where all cerebrovascular events are treated exclusively at the
participating centers. All patients undergoing SAVR were scheduled
for follow-up visits at 3 and 12 months. Thus, the follow-up data were
available from almost all patients. A major strength of our study is also
that in Finland each patient has a national identification code. This
allows the follow-up and identification of patients' date and cause of
death through the country. Nevertheless, the retrospective set-up
carries also some limitations. It does not allow characterization of the
study populations as accurately as in a prospective trial. An obvious
limitation is that the presence of AF during follow-up was based on
12-lead ECG recorded during routine 3- and 12-month follow-up
visits or in case of symptomatic AF episodes whereas no routine
Holter recordings were performed. Thus, it is likely that some epi-
sodes of asymptomatic paroxysmal AF were missed.
5 | CONCLUSIONS
In patients scheduled for SAVR with bioprosthesis, paroxysmal AF
was associated with increased mortality—particularly increased risk of
fatal strokes—and higher risk of developing permanent AF compared
to those with a history of sinus rhythm. Life-long anticoagulation
should be considered in these patients after the surgery.
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